A New Exact and More Powerful Unconditional Test of No Treatment Effect from Binary Matched Pairs

Biometrics ◽  
2007 ◽  
Vol 64 (3) ◽  
pp. 716-723 ◽  
Author(s):  
Chris J. Lloyd
2000 ◽  
Vol 16 (3) ◽  
pp. 147-149 ◽  
Author(s):  
Martin Grann

Summary: Hare's Psychopathy Checklist - Revised (PCL-R; Hare, 1991 ) was originally constructed for use among males in correctional and forensic settings. In this study, the PCL-R protocols of 36 matched pairs of female and male violent offenders were examined with respect to gender differences. The results indicated a few significant differences. By means of discriminant analysis, male Ss were distinguished from their female counterparts through their relatively higher scores on “callous/lack of empathy” (item 8) and “juvenile delinquency” (item 18), whereas the female Ss scored relatively higher on “promiscuous sexual behavior” (item 11). Some sources of bias and possible implications are discussed.


Methodology ◽  
2017 ◽  
Vol 13 (2) ◽  
pp. 41-60
Author(s):  
Shahab Jolani ◽  
Maryam Safarkhani

Abstract. In randomized controlled trials (RCTs), a common strategy to increase power to detect a treatment effect is adjustment for baseline covariates. However, adjustment with partly missing covariates, where complete cases are only used, is inefficient. We consider different alternatives in trials with discrete-time survival data, where subjects are measured in discrete-time intervals while they may experience an event at any point in time. The results of a Monte Carlo simulation study, as well as a case study of randomized trials in smokers with attention deficit hyperactivity disorder (ADHD), indicated that single and multiple imputation methods outperform the other methods and increase precision in estimating the treatment effect. Missing indicator method, which uses a dummy variable in the statistical model to indicate whether the value for that variable is missing and sets the same value to all missing values, is comparable to imputation methods. Nevertheless, the power level to detect the treatment effect based on missing indicator method is marginally lower than the imputation methods, particularly when the missingness depends on the outcome. In conclusion, it appears that imputation of partly missing (baseline) covariates should be preferred in the analysis of discrete-time survival data.


2007 ◽  
Author(s):  
Yun Zhang ◽  
Min Yu ◽  
Xinyue Zhou ◽  
Jingjing Lin ◽  
Yi Ni

2014 ◽  
Vol 23 (01) ◽  
pp. 49-55
Author(s):  
L. C. Hofbauer ◽  
D. Felsenberg ◽  
M. Amling ◽  
A. Kurth ◽  
P. Hadji

SummaryIt is important to understand compliance and persistence with medication use in the clinical practice of osteoporosis treatment. The purpose of this work is to describe the “intravenous ibandronate versus oral alendronate” (VIVA) study, a non-interventional trial to assess the compliance and persistence of osteopenic postmenopausal women with treatment via weekly oral alendronate or intravenous ibandronate (Bonviva®) every three months.4477 patients receiving ibandronate 3 mg i. v. quarterly and 1491 patients receiving alendronate 70 mg orally weekly were included in the study. Matched pairs of 901 subjects in each group were also generated. Matching was performed on the basis of age, body mass index, fracture history at study inclusion, prior treatment with bisphosphonates and the number of concomitant disorders. Secondary outcome measures of osteoporosis related fractures, mobility restriction and pain, analgesia, quality of life questionnaires as well as attitudes to medications were assessed. The primary outcome parameters of compliance and persistence will be tracked in these subjects.At baseline, the entire collectives differed significantly on body weight (less in ibandronate group), duration since osteo - porosis diagnosis (longer in ibandronate), and incidence of prior osteoporotic fracture (higher in ibandronate group). The matched-pairs differed only on mobility restriction and quality of life (both worse in ibandronate group).The results from the VIVA study trial will provide scientific rationale for clinical recommendations in the pharmacological treatment of postmenopausal osteoporosis.


Sign in / Sign up

Export Citation Format

Share Document